SCHEMBL22473352

SCHEMBL22473352

CC(C)(C)N1CCCC[C@@H]1c1ccn[nH]1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 1/20 0.45
WDR77 Q9BQA1 1/20 0.45
RIPK1 Q13546 1/20 0.43
CYP19A1 P11511 1/20 0.35
CYP11B2 P19099 1/20 0.35
CHRNB2 P17787 1/20 0.33
CHRNA7 P36544 1/20 0.33
CHRNA4 P43681 1/20 0.33
ADAM17 P78536 1/20 0.32
HSD11B1 P28845 2/20 0.32
CDK5 Q00535 1/20 0.32
CDK5R1 Q15078 1/20 0.32
PRCP P42785 1/20 0.31
CFB P00751 1/20 0.31
ROCK2 O75116 1/20 0.31
ROCK1 Q13464 1/20 0.31
CDC42BPA Q5VT25 1/20 0.31
CDC42BPB Q9Y5S2 1/20 0.31
CPT1A P50416 1/20 0.31
MAP4K4 O95819 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22473215 1.00 PRMT5 (0.45) PRMT5WDR77RIPK1CYP19A1CYP11B2
SCHEMBL22473353 0.81 PRMT5 (0.35) PRMT5WDR77RIPK1PRCPSLC6A4
SCHEMBL23492368 0.79 PRMT5 (0.45) PRMT5WDR77RIPK1CFB
SCHEMBL22473538 0.79 PRMT5 (0.45) PRMT5WDR77RIPK1CFB
SCHEMBL23491513 0.76 PRMT5 (0.43) PRMT5WDR77RIPK1CHRNB2CHRNA7
SCHEMBL22473473 0.76 SCN9A (0.40) PRMT5WDR77RIPK1CYP19A1CYP11B2
SCHEMBL23491988 0.76 SCN9A (0.40) PRMT5WDR77RIPK1CYP19A1CYP11B2
SCHEMBL22473163 0.76 SCN9A (0.40) PRMT5WDR77RIPK1CYP19A1CYP11B2
SCHEMBL22473214 0.76 PRMT5 (0.42) PRMT5WDR77RIPK1CYP19A1CYP11B2
SCHEMBL22473534 0.76 PRMT5 (0.42) PRMT5WDR77RIPK1CYP19A1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210171516-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2021-06-10 US disclosed
US-10787446-B2 Therapeutic compounds and methods of use thereof GENENTECH, INC. (US) 2020-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10787446-B2 Therapeutic compounds and methods of use thereof AVPR1B, C3AR1, RHEB PRMT5 92/4885WDR77 589/4885RIPK1 3202/4885
US-20210171516-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF AVPR1B, C3AR1, RHEB PRMT5 92/4885WDR77 589/4885RIPK1 3202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.